Comparative evaluation of mono- and polyclonal antibodies used in identification of interferon alpha-2b products

Quality control of recombinant interferon (rIFN) products with the help of modern analytical methods, including those used for identification, is becoming increasingly relevant nowadays. Identification is especially challenging in the case of Russian rIFN products that contain not only interferon (IFN) alpha-2b, but also other active ingredients and excipients that hinder the use of physical and chemical methods. Manufacturers of such products use IFN neutralization assay with mono- and/or polyclonal antibodies for identification. The aim of the study was to assess the feasibility of using different types of antibodies in the identification test based on neutralization of IFN antiviral activity in IFN alpha-2b products containing other active ingredients and excipients in addition to IFN. Materials and methods: the following materials were used in the study: MDBK cells, vesicular stomatitis virus, samples of IFN alpha-2b products with different composition and by different manufacturers, mono- and polyclonal antibodies by different manufacturers. Identification of rINFs was carried out by a biological method based on neutralization by specific antibodies of IFN ability to suppress the cytopathic effect of the indicator virus in a cell culture using a reference standard for comparison. Results: both polyclonal and monoclonal antibodies were shown to neutralize the activity of the tested IFN alpha-2b substances. Polyclonal antibodies interact with all products containing the same active ingredients, irrespective of their composition. Monoclonal antibodies interact selectively with some products. Conclusions: polyclonal antibodies can be used for identification of any product containing IFN alpha-2b. The use of monoclonal antibodies for this purpose is limited and depends on the composition of the product.

1. Li SF, Gong MJ, Zhao FR, Shao JJ, Xie YL, Zang YG, et al. Type I interferons: distinct biological activities and current applications for viral infection. Cell Physiol Biochem. 2018;51(5):2377–96. https://doi.org/10.1159/000495897

2. Wang H, Hu H, Zhang K. Overview of interferon: characteristics, signaling and anti-cancer effect. Arch Biotechnol Biomed. 2017;1:001–016. https://doi.org/10.29328/journal.hjb.1001001

3. Bekisz J, Baron S, Balinsky C, Morrow A, Zoon KS. Antiproliferative properties of type I and type II interferon. Pharmaceuticals (Basel). 2010;3(4):994–1015. https://doi.org/10.3390/ph3040994

4. Bogdan C, Mattner J, Schleicher U. The role of type I interferons in non-viral infections. Immunol. Rev. 2004;202:33–48. https://doi.org/10.1111/j.0105-2896

5. Wang YS, Youngster S, Grace M, Bausch J, Bordens R, Wyss DF. Structural and biological characterization of pegylated recombinant interferon alfa-2b and its therapeutic implications. Adv Drug Deliv Rev. 2002;54(4):547–70. https://doi.org/10.1016/s0169-409x(02)00027-3

6. Ershov FI, Kiselev OI. Interferons and their inducers (from molecules to drugs). Moscow: GEOTAR-Media; 2005 (In Russ.)

7. Khaitov RM. Immunology. Moscow: GEOTAR-Media; 2013 (In Russ.)

8. Banshero J, Palukka AK, Paskual B, Prilliman K. Monoclonal antibodies against interferon-alpha and methods of application. Patent of the Russian Federation № 2431638; 2011 (In Russ.)

9. Altshuler E, Serebryanaya D, Katrukha A. Preparation of recombinant antibodies and ways to increase their affinity. Uspechi biologicheskoi khimii = Advances in biological Chemistry. 2010;50:203–58 (In Russ.)

10. Male D, Brostoff J, Rot DB, Roitt A. Immunology. Moscow: Logosfera; 2007 (In Russ.)